Saman Daroo 8 Knowledge-based Company
Supporter of Hemophilia Patients
،
Committed to Improving and Enhancing the Quality of Life for Patients with Special Diseases
Saman Daroo 8, with the aim of producing recombinant human Factor VIII (rFVIII) and over a decade of experience, was introduced to the market in 2015 under the brand name SAFACTO AF. Leveraging advanced technologies and establishing a modern factory in the Khorasan Razavi Science and Technology Park, this company produces high-quality biotechnology products and has the capability to cover 100% of the market share for recombinant Factor VIII in Iran.
With the vision of becoming one of the top three biotech companies in the country and relying on expert human resources, Saman Daroo 8 continues to develop and enhance its products.
Innovation and Quality along with Success
Quality is the result of intelligent and continuous effort, not an accident!
Quality Assurance
The quality and safety of products at Saman Daroo are ensured through GMP and advanced technology.
Patient Support
Objective: Supporting patients, enhancing satisfaction and providing an exceptional treatment experience, and improving lives.
Superior Technology
Manufacturing medicines with high standards, advanced technology, and dedicated personnel.
Economic Quality
Superior technology at affordable costs for patients, without compromising the quality of medications.
Safacto AF
Recombinant Human Coagulation Factor VIII
-
Moroctocog Alfa
Safacto AF is produced using recombinant DNA technology and its functionality is similar to Factor VIII in the body. Injecting Safacto AF increases the plasma levels of Factor VIII and can temporarily address the clotting issues in patients with hemophilia type A.
- For Surgical Procedures
- For Treatment and Control of Bleeding
- Preventive Regimen to Reduce the Frequency of Bleeding